TY - JOUR
T1 - Efficacy and safety of 4-weekly cabazitaxel for castration-resistant prostate cancer
T2 - a multi-institutional study
AU - Shiota, Masaki
AU - Nakamura, Motonobu
AU - Yokomizo, Akira
AU - Tomoda, Toshihisa
AU - Sakamoto, Naotaka
AU - Seki, Narihito
AU - Hasegawa, Shuji
AU - Yunoki, Takakazu
AU - Harano, Masahiko
AU - Kuroiwa, Kentaro
AU - Eto, Masatoshi
N1 - Funding Information:
supported by JSPS KAKENHI Grant
Funding Information:
We would like to acknowledge the contributions of the following collaborators: Akito Yamaguchi (Harasanshin Hospital, Fukuoka), Takashi Dejima (Kyushu Central Hospital, Fukuoka), Satoshi Otsubo (Kitakyushu Municipal Medical Center, Kitakyushu), Akio Tsutsui (JCHO Kyushu Hospital, Kitakyushu), and Yoshifumi Hori (Miyazaki Prefectural Miyazaki Hospital, Miyazaki). We thank Anne M. O?Rourke, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.
Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Objective: This study aimed to reveal the efficacy and safety profiles of 4-weekly cabazitaxel in patients with castration-resistant prostate cancer (CRPC). Methods: The study included 62 Japanese patients who were treated for CRPC with ≥ 2 courses of cabazitaxel between 2014 and 2017. The oncological outcomes and adverse events were compared between 16 (25.8%) and 46 (74.2%) men who were treated with standard 3-weekly and alternative 4-weekly regimens, respectively. Results: The prostate-specific antigen (PSA) response was comparable between the 3-weekly and 4-weekly regimens (median [interquartile range]: − 9.9% [− 64.5 to 13.0%] and − 30.7% [− 52.8 to 10.9%], P = 0.89), respectively. For patients on the 4-weekly regimen, the risks of progression (hazard ratio [HR], 95% confidence interval [CI] 1.27, 0.71–2.43, P = 0.44), treatment failure (HR, 95% CI 0.84, 0.48–1.55, P = 0.57) and any-cause mortality (HR, 95% CI 1.09, 0.58–2.17, P = 0.79) were comparable to those for patients on the 3-weekly regimen. The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens. Conclusions: 3-weekly and 4-weekly regimens of cabazitaxel showed similar efficacy and safety profiles in a real-world clinical setting. These data suggest that a 4-weekly regimen may be acceptable for selected patients.
AB - Objective: This study aimed to reveal the efficacy and safety profiles of 4-weekly cabazitaxel in patients with castration-resistant prostate cancer (CRPC). Methods: The study included 62 Japanese patients who were treated for CRPC with ≥ 2 courses of cabazitaxel between 2014 and 2017. The oncological outcomes and adverse events were compared between 16 (25.8%) and 46 (74.2%) men who were treated with standard 3-weekly and alternative 4-weekly regimens, respectively. Results: The prostate-specific antigen (PSA) response was comparable between the 3-weekly and 4-weekly regimens (median [interquartile range]: − 9.9% [− 64.5 to 13.0%] and − 30.7% [− 52.8 to 10.9%], P = 0.89), respectively. For patients on the 4-weekly regimen, the risks of progression (hazard ratio [HR], 95% confidence interval [CI] 1.27, 0.71–2.43, P = 0.44), treatment failure (HR, 95% CI 0.84, 0.48–1.55, P = 0.57) and any-cause mortality (HR, 95% CI 1.09, 0.58–2.17, P = 0.79) were comparable to those for patients on the 3-weekly regimen. The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens. Conclusions: 3-weekly and 4-weekly regimens of cabazitaxel showed similar efficacy and safety profiles in a real-world clinical setting. These data suggest that a 4-weekly regimen may be acceptable for selected patients.
UR - http://www.scopus.com/inward/record.url?scp=85066157705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066157705&partnerID=8YFLogxK
U2 - 10.1007/s00280-019-03874-7
DO - 10.1007/s00280-019-03874-7
M3 - Article
C2 - 31115605
AN - SCOPUS:85066157705
SN - 0344-5704
VL - 84
SP - 561
EP - 566
JO - Cancer chemotherapy and pharmacology
JF - Cancer chemotherapy and pharmacology
IS - 3
ER -
